Financial Daily from THE HINDU group of publications
Friday, Nov 11, 2005


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Home Page - Health
Industry & Economy - Pharmaceuticals
Government - Policy


Ministry permits generic cos to make bird flu drug

Nithya Subramanian

New Delhi , Nov. 10

THE Industry Ministry has given a green signal for allowing domestic pharmaceutical companies to manufacture generic versions of Tamiflu (oseltamivir), considered the most effective drug to treat avian influenza, commonly called bird flu.

Clearing the air surrounding the patents for the drug filed by Swiss drug major Roche and the innovator company, Gilead Sciences, the Ministry has said that under the present policy a compulsory license is not necessary, as a product patent has not yet been granted for the molecule. In fact, the nearly half-a-dozen patents pending in the Mail Box do not cover the molecule, but are for some of its intermediate compounds, said top Government officials.

"So far, only a process patent has been granted for Tamiflu and not a product patent. Therefore, generic companies who want to follow the same process to manufacture the drug would have to seek permission from the innovator," added officials.

According to Government sources, the Industry Ministry conveyed this to representatives of an inter-Ministerial Committee set up to tackle the bird flu outbreak at a meeting held earlier in the week.

"Also, Roche has been granted marketing rights for Tamiflu in India," they said.

At present, three Indian companies, Cipla, Ranbaxy and Hetero, have stated that they are ready to manufacture the drugs. Mr Malvinder Mohan Singh, President - Pharmaceuticals, Ranbaxy, today reiterated that the company is capable of manufacturing the drug in lab scale. "We are now preparing for commercial production. We have had discussions with Roche and are expecting a decision soon," he said.

Roche has indicated that it has received about 150 requests for licenses to manufacture the drug, and has already held discussions with eight possible partners.

It expects to shortlist the candidates later this month.

Meanwhile, domestic industry is of the view that just like other South-East Asian countries, Government must be ready with a concrete plan to tackle the spread of bird flu. Officials said that companies have asked the Government to give it some indication of the size of the order, so that it could make investments in sourcing raw materials and manufacturing the drugs.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
FDI boost: Transfer of financial services co shares may come under automatic route


Entry norms eased, licence fee cut for NLD, ILD players — Long distance phone tariffs set to drop
Ministry permits generic cos to make bird flu drug
Ranbaxy wins process patent verdict on Pfizer drug in Norway
Rs 900-cr unit in Jamshedpur — Tata Steel to tie up with BlueScope
Intergraph CEO sees growth in spatial, GIS market
`Processors driving changes in embedded design'
Flextronics Soft rolls out corporate ethics to its merged entities
Satyam exits Sify; entire stake sold to Infinity Capital of US for $62.62 m


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line